TLR4 and dilated cardiomyopathy: Shengmai Injection can regulate Toll-like receptor 4 (TLR4) and NF-κB protein levels to inhibit inflammatory factors downstream of TLR4/NF-κB signaling pathway, thereby improving cardiac dysfunction, reducing myocardial injury, and arresting heart failure in rats with dilated cardiomyopathy [70].